gene_symbol
IGHG1
hgnc_id
HGNC:5525
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Engineered NK cells bind the IgG1 Fc of therapeutic antibodies (e.g., tafasitamab) and mediate ADCC against antibody-opsonized CD19+ B cells via perforin/granzyme; the IgG1 Fc itself is not a cell-expressed target.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Ligand for the engineered Fc receptor (PluReceptor) on NK cells; engages therapeutic IgG1 antibodies such as tafasitamab-cxix to mediate ADCC against opsonized CD19+ B cells.
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06434363
disease_id_num_tar_ref
2174
drug_id_num_tar_ref
5806